Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies Article Swipe

View

Chie Emoto , Kosuke Doki , Yuki Matsumoto , Shinichi Kijima , Mikiko Nakamura , Tsuyoshi Fukuda ·

YOU? · · 2020 · Open Access · · DOI: https://doi.org/10.3999/jscpt.51.331

The utilization of a physiologically-based pharmacokinetic (PBPK) model has become prevalent, especially in drug development by pharmaceutical companies. The regulatory agencies in the US and Europe have already issued guidelines while the Japanese agency is preparing one to support the process. To some extent, applications of PBPK modeling to assess the risk of drug-drug interaction have mainly been discussed. It has been limited to discussing other utilizations such as: 1) conducting a virtual bioequivalence study for a new formulation; 2) assessing PK changes in a Japanese population; and 3) predicting PK profiles of drugs or drug candidates in pediatric subjects. The purpose of this paper is to discuss the current status and future challenges of potential utilizations of PBPK modeling through actual practices and to share regulatory experiences on PBPK modeling in Japan. We summarize the discussions on prospects from the perspective of industry, academia, regulatory agencies, and hospitals.

Related Topics

Public Administration

Philosophy

Concepts

Physiologically based pharmacokinetic modelling Bioequivalence Medicine Pharmacology Regulatory science Drug development Drug Management science Agency (philosophy) Regulatory agency Risk analysis (engineering) Engineering ethics Pharmacokinetics Engineering Political science Pathology Epistemology Public administration Philosophy

Metadata

Type: article
Language: en
Landing Page: https://doi.org/10.3999/jscpt.51.331
OA Status: diamond
References: 36
Related Works: 10
OpenAlex ID: https://openalex.org/W3121787478

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W3121787478

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.3999/jscpt.51.331

Digital Object Identifier
Title: Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies

Work title
Type: article

OpenAlex work type
Language: en

Primary language
Publication year: 2020

Year of publication
Publication date: 2020-11-30

Full publication date if available
Authors: Chie Emoto, Kosuke Doki, Yuki Matsumoto, Shinichi Kijima, Mikiko Nakamura, Tsuyoshi Fukuda

List of authors in order
Landing page: https://doi.org/10.3999/jscpt.51.331

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: diamond

Open access status per OpenAlex
OA URL: https://doi.org/10.3999/jscpt.51.331

Direct OA link when available
Concepts: Physiologically based pharmacokinetic modelling, Bioequivalence, Medicine, Pharmacology, Regulatory science, Drug development, Drug, Management science, Agency (philosophy), Regulatory agency, Risk analysis (engineering), Engineering ethics, Pharmacokinetics, Engineering, Political science, Pathology, Epistemology, Public administration, Philosophy

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
References (count): 36

Number of works referenced by this work
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W3121787478
doi	https://doi.org/10.3999/jscpt.51.331
ids.doi	https://doi.org/10.3999/jscpt.51.331
ids.mag	3121787478
ids.openalex	https://openalex.org/W3121787478
fwci	0.0
type	article
title	Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies
biblio.issue	6
biblio.volume	51
biblio.last_page	344
biblio.first_page	331
topics[0].id	https://openalex.org/T10804
topics[0].field.id	https://openalex.org/fields/20
topics[0].field.display_name	Economics, Econometrics and Finance
topics[0].score	0.8804000020027161
topics[0].domain.id	https://openalex.org/domains/2
topics[0].domain.display_name	Social Sciences
topics[0].subfield.id	https://openalex.org/subfields/2002
topics[0].subfield.display_name	Economics and Econometrics
topics[0].display_name	Health Systems, Economic Evaluations, Quality of Life
topics[1].id	https://openalex.org/T11235
topics[1].field.id	https://openalex.org/fields/26
topics[1].field.display_name	Mathematics
topics[1].score	0.8632000088691711
topics[1].domain.id	https://openalex.org/domains/3
topics[1].domain.display_name	Physical Sciences
topics[1].subfield.id	https://openalex.org/subfields/2613
topics[1].subfield.display_name	Statistics and Probability
topics[1].display_name	Statistical Methods in Clinical Trials
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C185867374
concepts[0].level	3
concepts[0].score	0.9406790137290955
concepts[0].wikidata	https://www.wikidata.org/wiki/Q2562769
concepts[0].display_name	Physiologically based pharmacokinetic modelling
concepts[1].id	https://openalex.org/C42404028
concepts[1].level	3
concepts[1].score	0.6060187816619873
concepts[1].wikidata	https://www.wikidata.org/wiki/Q864940
concepts[1].display_name	Bioequivalence
concepts[2].id	https://openalex.org/C71924100
concepts[2].level	0
concepts[2].score	0.4859865605831146
concepts[2].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[2].display_name	Medicine
concepts[3].id	https://openalex.org/C98274493
concepts[3].level	1
concepts[3].score	0.48587220907211304
concepts[3].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[3].display_name	Pharmacology
concepts[4].id	https://openalex.org/C2778917124
concepts[4].level	2
concepts[4].score	0.48514804244041443
concepts[4].wikidata	https://www.wikidata.org/wiki/Q7309705
concepts[4].display_name	Regulatory science
concepts[5].id	https://openalex.org/C64903051
concepts[5].level	3
concepts[5].score	0.45246386528015137
concepts[5].wikidata	https://www.wikidata.org/wiki/Q2198549
concepts[5].display_name	Drug development
concepts[6].id	https://openalex.org/C2780035454
concepts[6].level	2
concepts[6].score	0.43983709812164307
concepts[6].wikidata	https://www.wikidata.org/wiki/Q8386
concepts[6].display_name	Drug
concepts[7].id	https://openalex.org/C539667460
concepts[7].level	1
concepts[7].score	0.42951327562332153
concepts[7].wikidata	https://www.wikidata.org/wiki/Q2414942
concepts[7].display_name	Management science
concepts[8].id	https://openalex.org/C108170787
concepts[8].level	2
concepts[8].score	0.4183812737464905
concepts[8].wikidata	https://www.wikidata.org/wiki/Q3951828
concepts[8].display_name	Agency (philosophy)
concepts[9].id	https://openalex.org/C3019398576
concepts[9].level	2
concepts[9].score	0.4159621298313141
concepts[9].wikidata	https://www.wikidata.org/wiki/Q1639780
concepts[9].display_name	Regulatory agency
concepts[10].id	https://openalex.org/C112930515
concepts[10].level	1
concepts[10].score	0.3835752606391907
concepts[10].wikidata	https://www.wikidata.org/wiki/Q4389547
concepts[10].display_name	Risk analysis (engineering)
concepts[11].id	https://openalex.org/C55587333
concepts[11].level	1
concepts[11].score	0.3508044481277466
concepts[11].wikidata	https://www.wikidata.org/wiki/Q1133029
concepts[11].display_name	Engineering ethics
concepts[12].id	https://openalex.org/C112705442
concepts[12].level	2
concepts[12].score	0.3301682472229004
concepts[12].wikidata	https://www.wikidata.org/wiki/Q323936
concepts[12].display_name	Pharmacokinetics
concepts[13].id	https://openalex.org/C127413603
concepts[13].level	0
concepts[13].score	0.231673002243042
concepts[13].wikidata	https://www.wikidata.org/wiki/Q11023
concepts[13].display_name	Engineering
concepts[14].id	https://openalex.org/C17744445
concepts[14].level	0
concepts[14].score	0.16147536039352417
concepts[14].wikidata	https://www.wikidata.org/wiki/Q36442
concepts[14].display_name	Political science
concepts[15].id	https://openalex.org/C142724271
concepts[15].level	1
concepts[15].score	0.0
concepts[15].wikidata	https://www.wikidata.org/wiki/Q7208
concepts[15].display_name	Pathology
concepts[16].id	https://openalex.org/C111472728
concepts[16].level	1
concepts[16].score	0.0
concepts[16].wikidata	https://www.wikidata.org/wiki/Q9471
concepts[16].display_name	Epistemology
concepts[17].id	https://openalex.org/C3116431
concepts[17].level	1
concepts[17].score	0.0
concepts[17].wikidata	https://www.wikidata.org/wiki/Q31728
concepts[17].display_name	Public administration
concepts[18].id	https://openalex.org/C138885662
concepts[18].level	0
concepts[18].score	0.0
concepts[18].wikidata	https://www.wikidata.org/wiki/Q5891
concepts[18].display_name	Philosophy
keywords[0].id	https://openalex.org/keywords/physiologically-based-pharmacokinetic-modelling
keywords[0].score	0.9406790137290955
keywords[0].display_name	Physiologically based pharmacokinetic modelling
keywords[1].id	https://openalex.org/keywords/bioequivalence
keywords[1].score	0.6060187816619873
keywords[1].display_name	Bioequivalence
keywords[2].id	https://openalex.org/keywords/medicine
keywords[2].score	0.4859865605831146
keywords[2].display_name	Medicine
keywords[3].id	https://openalex.org/keywords/pharmacology
keywords[3].score	0.48587220907211304
keywords[3].display_name	Pharmacology
keywords[4].id	https://openalex.org/keywords/regulatory-science
keywords[4].score	0.48514804244041443
keywords[4].display_name	Regulatory science
keywords[5].id	https://openalex.org/keywords/drug-development
keywords[5].score	0.45246386528015137
keywords[5].display_name	Drug development
keywords[6].id	https://openalex.org/keywords/drug
keywords[6].score	0.43983709812164307
keywords[6].display_name	Drug
keywords[7].id	https://openalex.org/keywords/management-science
keywords[7].score	0.42951327562332153
keywords[7].display_name	Management science
keywords[8].id	https://openalex.org/keywords/agency
keywords[8].score	0.4183812737464905
keywords[8].display_name	Agency (philosophy)
keywords[9].id	https://openalex.org/keywords/regulatory-agency
keywords[9].score	0.4159621298313141
keywords[9].display_name	Regulatory agency
keywords[10].id	https://openalex.org/keywords/risk-analysis
keywords[10].score	0.3835752606391907
keywords[10].display_name	Risk analysis (engineering)
keywords[11].id	https://openalex.org/keywords/engineering-ethics
keywords[11].score	0.3508044481277466
keywords[11].display_name	Engineering ethics
keywords[12].id	https://openalex.org/keywords/pharmacokinetics
keywords[12].score	0.3301682472229004
keywords[12].display_name	Pharmacokinetics
keywords[13].id	https://openalex.org/keywords/engineering
keywords[13].score	0.231673002243042
keywords[13].display_name	Engineering
keywords[14].id	https://openalex.org/keywords/political-science
keywords[14].score	0.16147536039352417
keywords[14].display_name	Political science
language	en
locations[0].id	doi:10.3999/jscpt.51.331
locations[0].is_oa	True
locations[0].source.id	https://openalex.org/S2764687680
locations[0].source.issn	0388-1601, 1882-8272
locations[0].source.type	journal
locations[0].source.is_oa	True
locations[0].source.issn_l	0388-1601
locations[0].source.is_core	False
locations[0].source.is_in_doaj	False
locations[0].source.display_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
locations[0].source.host_organization
locations[0].source.host_organization_name
locations[0].source.host_organization_lineage
locations[0].license
locations[0].pdf_url
locations[0].version	publishedVersion
locations[0].raw_type	journal-article
locations[0].license_id
locations[0].is_accepted	True
locations[0].is_published	True
locations[0].raw_source_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
locations[0].landing_page_url	https://doi.org/10.3999/jscpt.51.331
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5061739010
authorships[0].author.orcid	https://orcid.org/0000-0002-8933-0254
authorships[0].author.display_name	Chie Emoto
authorships[0].countries	JP, US
authorships[0].affiliations[0].institution_ids	https://openalex.org/I8873088
authorships[0].affiliations[0].raw_affiliation_string	Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Japan
authorships[0].affiliations[1].institution_ids	https://openalex.org/I1285204247
authorships[0].affiliations[1].raw_affiliation_string	Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, USA
authorships[0].institutions[0].id	https://openalex.org/I8873088
authorships[0].institutions[0].ror	https://ror.org/053e8a708
authorships[0].institutions[0].type	education
authorships[0].institutions[0].lineage	https://openalex.org/I8873088
authorships[0].institutions[0].country_code	JP
authorships[0].institutions[0].display_name	Showa Pharmaceutical University
authorships[0].institutions[1].id	https://openalex.org/I1285204247
authorships[0].institutions[1].ror	https://ror.org/01hcyya48
authorships[0].institutions[1].type	healthcare
authorships[0].institutions[1].lineage	https://openalex.org/I1285204247
authorships[0].institutions[1].country_code	US
authorships[0].institutions[1].display_name	Cincinnati Children's Hospital Medical Center
authorships[0].author_position	first
authorships[0].raw_author_name	Chie EMOTO
authorships[0].is_corresponding	False
authorships[0].raw_affiliation_strings	Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, USA, Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Japan
authorships[1].author.id	https://openalex.org/A5031741885
authorships[1].author.orcid	https://orcid.org/0000-0003-2497-0063
authorships[1].author.display_name	Kosuke Doki
authorships[1].countries	JP
authorships[1].affiliations[0].institution_ids	https://openalex.org/I146399215
authorships[1].affiliations[0].raw_affiliation_string	Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Japan
authorships[1].institutions[0].id	https://openalex.org/I146399215
authorships[1].institutions[0].ror	https://ror.org/02956yf07
authorships[1].institutions[0].type	education
authorships[1].institutions[0].lineage	https://openalex.org/I146399215
authorships[1].institutions[0].country_code	JP
authorships[1].institutions[0].display_name	University of Tsukuba
authorships[1].author_position	middle
authorships[1].raw_author_name	Kosuke DOKI
authorships[1].is_corresponding	False
authorships[1].raw_affiliation_strings	Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Japan
authorships[2].author.id	https://openalex.org/A5101753795
authorships[2].author.orcid	https://orcid.org/0000-0002-4938-5728
authorships[2].author.display_name	Yuki Matsumoto
authorships[2].countries	JP
authorships[2].affiliations[0].institution_ids	https://openalex.org/I4210108032
authorships[2].affiliations[0].raw_affiliation_string	Clinical Pharmacokinetics & Pharmacometrics Group, Clinical Pharmacology Development, Clinical Research, Japan Development, MSD K. K., Japan
authorships[2].institutions[0].id	https://openalex.org/I4210108032
authorships[2].institutions[0].ror	https://ror.org/01kaqxm37
authorships[2].institutions[0].type	company
authorships[2].institutions[0].lineage	https://openalex.org/I1285764155, https://openalex.org/I4210108032
authorships[2].institutions[0].country_code	JP
authorships[2].institutions[0].display_name	MSD K.K. (Japan)
authorships[2].author_position	middle
authorships[2].raw_author_name	Yuki MATSUMOTO
authorships[2].is_corresponding	False
authorships[2].raw_affiliation_strings	Clinical Pharmacokinetics & Pharmacometrics Group, Clinical Pharmacology Development, Clinical Research, Japan Development, MSD K. K., Japan
authorships[3].author.id	https://openalex.org/A5042028051
authorships[3].author.orcid	https://orcid.org/0000-0002-8624-5628
authorships[3].author.display_name	Shinichi Kijima
authorships[3].countries	JP
authorships[3].affiliations[0].institution_ids	https://openalex.org/I91962293
authorships[3].affiliations[0].raw_affiliation_string	Pharmaceuticals and Medical Devices Agency (PMDA), Japan
authorships[3].institutions[0].id	https://openalex.org/I91962293
authorships[3].institutions[0].ror	https://ror.org/03mpkb302
authorships[3].institutions[0].type	government
authorships[3].institutions[0].lineage	https://openalex.org/I91962293
authorships[3].institutions[0].country_code	JP
authorships[3].institutions[0].display_name	Pharmaceuticals and Medical Devices Agency
authorships[3].author_position	middle
authorships[3].raw_author_name	Shinichi KIJIMA
authorships[3].is_corresponding	False
authorships[3].raw_affiliation_strings	Pharmaceuticals and Medical Devices Agency (PMDA), Japan
authorships[4].author.id	https://openalex.org/A5017212730
authorships[4].author.orcid	https://orcid.org/0000-0002-0842-1710
authorships[4].author.display_name	Mikiko Nakamura
authorships[4].affiliations[0].raw_affiliation_string	Pharmacometrics Group, Clinical Pharmacology Dept., Chugai Pharmaceutical Co., LTD., Japan
authorships[4].author_position	middle
authorships[4].raw_author_name	Mikiko NAKAMURA
authorships[4].is_corresponding	False
authorships[4].raw_affiliation_strings	Pharmacometrics Group, Clinical Pharmacology Dept., Chugai Pharmaceutical Co., LTD., Japan
authorships[5].author.id	https://openalex.org/A5013881333
authorships[5].author.orcid	https://orcid.org/0000-0002-0477-3102
authorships[5].author.display_name	Tsuyoshi Fukuda
authorships[5].countries	JP
authorships[5].affiliations[0].institution_ids	https://openalex.org/I8873088
authorships[5].affiliations[0].raw_affiliation_string	Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Japan
authorships[5].affiliations[1].institution_ids	https://openalex.org/I4210132193
authorships[5].affiliations[1].raw_affiliation_string	National Center for Child Health and Development, Japan
authorships[5].institutions[0].id	https://openalex.org/I4210132193
authorships[5].institutions[0].ror	https://ror.org/03fvwxc59
authorships[5].institutions[0].type	government
authorships[5].institutions[0].lineage	https://openalex.org/I4210132193
authorships[5].institutions[0].country_code	JP
authorships[5].institutions[0].display_name	National Center For Child Health and Development
authorships[5].institutions[1].id	https://openalex.org/I8873088
authorships[5].institutions[1].ror	https://ror.org/053e8a708
authorships[5].institutions[1].type	education
authorships[5].institutions[1].lineage	https://openalex.org/I8873088
authorships[5].institutions[1].country_code	JP
authorships[5].institutions[1].display_name	Showa Pharmaceutical University
authorships[5].author_position	last
authorships[5].raw_author_name	Tsuyoshi FUKUDA
authorships[5].is_corresponding	False
authorships[5].raw_affiliation_strings	Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Japan, National Center for Child Health and Development, Japan
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.3999/jscpt.51.331
open_access.oa_status	diamond
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Applications of PBPK Modeling and Simulations in The Clinical Pharmacology Field: Lessons from Several Case Studies
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10804
primary_topic.field.id	https://openalex.org/fields/20
primary_topic.field.display_name	Economics, Econometrics and Finance
primary_topic.score	0.8804000020027161
primary_topic.domain.id	https://openalex.org/domains/2
primary_topic.domain.display_name	Social Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2002
primary_topic.subfield.display_name	Economics and Econometrics
primary_topic.display_name	Health Systems, Economic Evaluations, Quality of Life
related_works	https://openalex.org/W4311504610, https://openalex.org/W2134794720, https://openalex.org/W1940611598, https://openalex.org/W2313985930, https://openalex.org/W4311934119, https://openalex.org/W2999793242, https://openalex.org/W149633284, https://openalex.org/W2134695639, https://openalex.org/W1537699525, https://openalex.org/W3197060680
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.3999/jscpt.51.331
best_oa_location.is_oa	True
best_oa_location.source.id	https://openalex.org/S2764687680
best_oa_location.source.issn	0388-1601, 1882-8272
best_oa_location.source.type	journal
best_oa_location.source.is_oa	True
best_oa_location.source.issn_l	0388-1601
best_oa_location.source.is_core	False
best_oa_location.source.is_in_doaj	False
best_oa_location.source.display_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
best_oa_location.source.host_organization
best_oa_location.source.host_organization_name
best_oa_location.source.host_organization_lineage
best_oa_location.license
best_oa_location.pdf_url
best_oa_location.version	publishedVersion
best_oa_location.raw_type	journal-article
best_oa_location.license_id
best_oa_location.is_accepted	True
best_oa_location.is_published	True
best_oa_location.raw_source_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
best_oa_location.landing_page_url	https://doi.org/10.3999/jscpt.51.331
primary_location.id	doi:10.3999/jscpt.51.331
primary_location.is_oa	True
primary_location.source.id	https://openalex.org/S2764687680
primary_location.source.issn	0388-1601, 1882-8272
primary_location.source.type	journal
primary_location.source.is_oa	True
primary_location.source.issn_l	0388-1601
primary_location.source.is_core	False
primary_location.source.is_in_doaj	False
primary_location.source.display_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
primary_location.source.host_organization
primary_location.source.host_organization_name
primary_location.source.host_organization_lineage
primary_location.license
primary_location.pdf_url
primary_location.version	publishedVersion
primary_location.raw_type	journal-article
primary_location.license_id
primary_location.is_accepted	True
primary_location.is_published	True
primary_location.raw_source_name	Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
primary_location.landing_page_url	https://doi.org/10.3999/jscpt.51.331
publication_date	2020-11-30
publication_year	2020
referenced_works	https://openalex.org/W1501209109, https://openalex.org/W2741525634, https://openalex.org/W2061674370, https://openalex.org/W2587355458, https://openalex.org/W1501922076, https://openalex.org/W2073430961, https://openalex.org/W2793389242, https://openalex.org/W2214717060, https://openalex.org/W2894058867, https://openalex.org/W2322172135, https://openalex.org/W2089133581, https://openalex.org/W2899444542, https://openalex.org/W2077656434, https://openalex.org/W2510513174, https://openalex.org/W1972576782, https://openalex.org/W2122527560, https://openalex.org/W1968101595, https://openalex.org/W2781529431, https://openalex.org/W136637431, https://openalex.org/W2444137400, https://openalex.org/W2896572723, https://openalex.org/W2560422329, https://openalex.org/W2809590864, https://openalex.org/W1979930569, https://openalex.org/W2120416054, https://openalex.org/W2035133162, https://openalex.org/W2536389288, https://openalex.org/W2772600154, https://openalex.org/W2341095449, https://openalex.org/W2987609484, https://openalex.org/W2620740115, https://openalex.org/W2945006629, https://openalex.org/W2889520783, https://openalex.org/W2971302648, https://openalex.org/W2341647963, https://openalex.org/W2783299760
referenced_works_count	36
abstract_inverted_index.a	3, 71, 76, 84
abstract_inverted_index.1)	69
abstract_inverted_index.2)	79
abstract_inverted_index.3)	88
abstract_inverted_index.It	59
abstract_inverted_index.PK	81, 90
abstract_inverted_index.To	41
abstract_inverted_index.US	23
abstract_inverted_index.We	133
abstract_inverted_index.by	15
abstract_inverted_index.in	12, 21, 83, 97, 131
abstract_inverted_index.is	34, 105
abstract_inverted_index.of	2, 45, 52, 92, 102, 114, 117, 142
abstract_inverted_index.on	128, 137
abstract_inverted_index.or	94
abstract_inverted_index.to	37, 48, 63, 106, 124
abstract_inverted_index.The	0, 18, 100
abstract_inverted_index.and	24, 87, 111, 123, 147
abstract_inverted_index.as:	68
abstract_inverted_index.for	75
abstract_inverted_index.has	8, 60
abstract_inverted_index.new	77
abstract_inverted_index.one	36
abstract_inverted_index.the	22, 31, 39, 50, 108, 135, 140
abstract_inverted_index.PBPK	46, 118, 129
abstract_inverted_index.been	57, 61
abstract_inverted_index.drug	13, 95
abstract_inverted_index.from	139
abstract_inverted_index.have	26, 55
abstract_inverted_index.risk	51
abstract_inverted_index.some	42
abstract_inverted_index.such	67
abstract_inverted_index.this	103
abstract_inverted_index.drugs	93
abstract_inverted_index.model	7
abstract_inverted_index.other	65
abstract_inverted_index.paper	104
abstract_inverted_index.share	125
abstract_inverted_index.study	74
abstract_inverted_index.while	30
abstract_inverted_index.(PBPK)	6
abstract_inverted_index.Europe	25
abstract_inverted_index.Japan.	132
abstract_inverted_index.actual	121
abstract_inverted_index.agency	33
abstract_inverted_index.assess	49
abstract_inverted_index.become	9
abstract_inverted_index.future	112
abstract_inverted_index.issued	28
abstract_inverted_index.mainly	56
abstract_inverted_index.status	110
abstract_inverted_index.already	27
abstract_inverted_index.changes	82
abstract_inverted_index.current	109
abstract_inverted_index.discuss	107
abstract_inverted_index.extent,	43
abstract_inverted_index.limited	62
abstract_inverted_index.purpose	101
abstract_inverted_index.support	38
abstract_inverted_index.through	120
abstract_inverted_index.virtual	72
abstract_inverted_index.Japanese	32, 85
abstract_inverted_index.agencies	20
abstract_inverted_index.modeling	47, 119, 130
abstract_inverted_index.process.	40
abstract_inverted_index.profiles	91
abstract_inverted_index.academia,	144
abstract_inverted_index.agencies,	146
abstract_inverted_index.assessing	80
abstract_inverted_index.drug-drug	53
abstract_inverted_index.industry,	143
abstract_inverted_index.pediatric	98
abstract_inverted_index.potential	115
abstract_inverted_index.practices	122
abstract_inverted_index.preparing	35
abstract_inverted_index.prospects	138
abstract_inverted_index.subjects.	99
abstract_inverted_index.summarize	134
abstract_inverted_index.candidates	96
abstract_inverted_index.challenges	113
abstract_inverted_index.companies.	17
abstract_inverted_index.conducting	70
abstract_inverted_index.discussed.	58
abstract_inverted_index.discussing	64
abstract_inverted_index.especially	11
abstract_inverted_index.guidelines	29
abstract_inverted_index.hospitals.	148
abstract_inverted_index.predicting	89
abstract_inverted_index.prevalent,	10
abstract_inverted_index.regulatory	19, 126, 145
abstract_inverted_index.development	14
abstract_inverted_index.discussions	136
abstract_inverted_index.experiences	127
abstract_inverted_index.interaction	54
abstract_inverted_index.perspective	141
abstract_inverted_index.population;	86
abstract_inverted_index.utilization	1
abstract_inverted_index.applications	44
abstract_inverted_index.formulation;	78
abstract_inverted_index.utilizations	66, 116
abstract_inverted_index.bioequivalence	73
abstract_inverted_index.pharmaceutical	16
abstract_inverted_index.pharmacokinetic	5
abstract_inverted_index.physiologically-based	4
cited_by_percentile_year
countries_distinct_count	2
institutions_distinct_count	6
citation_normalized_percentile.value	0.25019243
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False